REHOVOT, Israel, March 1,
2023 /PRNewswire/ -- Biomica, a clinical-stage
biopharmaceutical company developing innovative microbiome-based
therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE:
EVGN), today announced it will be presenting at the 2023 ECCO
Annual Meeting taking place in Copenhagen, Denmark from March 1 to 4, 2023.
The European Crohn's and Colitis Organization (ECCO) annual
congress is an international leading meeting focusing on
state-of-the-art clinical approaches and cutting-edge research and
advances in Inflammatory Bowel Diseases (IBD).
Professor Yehuda Ringel,
Biomica's Chief Scientific Officer (CSO), will be presenting recent
data from Biomica's IBD R&D pipeline.
Biomica's abstract entitled "Anti-inflammatory Effect
and Mechanism of Action of BMC333, a Rationally-Designed Live
Bacterial Consortium Based on Microbiome Functional Genomic
Analysis for Treating IBD", was selected for a poster
presentation and Professor Ringel will be presenting on the
conference Guided Poster Session on Friday,
March 3, 2023 between 12:30 and 13:30. The poster will also
be available as an e-Poster on the Virtual Congress Platform until
June 4, 2023 (presentation number:
P035).
Professor Ringel, will be available for one-on-one meetings
throughout the conference, and those interested should be in touch
with him directly or with Biomica's investor or public relations
team.
About Biomica Ltd.:
Biomica is a clinical stage biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing MicroBoost AI
tech engine, licensed from Evogene. Biomica aims to identify and
characterize disease-related microbiome entities and to develop
novel therapeutics based on these understandings. The company is
focused on the development of therapies for antibiotic resistant
bacteria, immuno-oncology, and microbiome-related gastrointestinal
(GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ:
EVGN) (TASE: EVGN).
For more information, please visit www.biomicamed.com.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
the probability of success while reducing development time and
cost. Evogene established three unique tech-engines –
MicroBoost AI, ChemPass
AI and GeneRator AI – leveraging Big Data
and Artificial Intelligence and incorporating deep
multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of
products based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by
Ag Plenus, medical cannabis products
by Canonic and castor varieties, for the biofuel and other
industries, by Casterra.
Contact :
Investor
Contact:
|
|
Kenny Green
Email:
kenny.green@evogene.com
Tel: +1 212 378
8040
|
Professor Yehuda
Ringel
Email:
Yehuda.Ringel@biomicamed.com
|
Logo -
https://mma.prnewswire.com/media/1974949/Biomica.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original
content:https://www.prnewswire.com/news-releases/biomica-cso-to-present-at-the-ecco-2023-annual-meeting-in-copenhagen-between-march-1-4-2023-301760097.html
SOURCE Biomica Ltd.